CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Obesity - Management
Which anti-obesity drug should I prescribe?
- Orlistat is the anti-obesity drugs of choice when drug treatment is considered to be appropriate in primary care. For further information see Scenario: Prescribing orlistat.
- Sibutramine is no longer prescribable in the UK — its marketing authorization has been suspended by the European Medicines Agency.
In depth
© NHS Institute for Innovation and Improvement